ストックスクリーナーアプリを入手
605.02
0.04%
-0.587
前日終値:
$605.61
開ける：
$606.89
24時間の取引高:
454.73K
Relative Volume:
0.46
時価総額：
$65.95B
収益：
$14.09B
当期純損益:
$4.50B
株価収益率:
15.40
EPS:
39.28
ネットキャッシュフロー:
$2.96B
1週間 パフォーマンス:
-0.90%
1か月 パフォーマンス:
+5.56%
6か月 パフォーマンス:
-27.02%
1年 パフォーマンス:
-36.75%
1日の値動き範囲:
$602.09
$611.04
1週間の範囲:
$542.44
$615.61
52週間の値動き範囲:
$525.99
$1,211.20
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
605.00 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.54 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
ARGX
Argen X Se Adr
|
654.29 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.17 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.97 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Aspire Growth Partners LLC Makes New $421,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Retinal Vein Occlusion Market Size, Trends & Growth Forecast - openPR.com
Mercer Global Advisors Inc. ADV Has $16.66 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Shares Gap Down After Earnings Miss - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Posts Quarterly Earnings Results, Misses Estimates By $0.61 EPS - MarketBeat
TD Waterhouse Canada Inc. Lowers Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Voleon Capital Management LP Acquires Shares of 671 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
AQR Capital Management LLC Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by The Manufacturers Life Insurance Company - MarketBeat
Northern Trust Corp Has $751.39 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Caisse DE Depot ET Placement DU Quebec - MarketBeat
Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria - MSN
Cantor Fitzgerald Issues Positive Outlook for REGN Earnings - MarketBeat
Westbourne Investments Inc. Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to “Hold” at StockNews.com - Defense World
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Nebula Research & Development LLC - MarketBeat
Regeneron (REGN) Declares Quarterly Dividend of $0.88/Share - GuruFocus
Retinal Vein Occlusion Market Projected To Witness Massive - openPR.com
Schonfeld Strategic Advisors LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition - insights.citeline.com
FY2025 EPS Estimates for REGN Raised by Cantor Fitzgerald - Defense World
Regeneron announces significant expansion of US manufacturing capacity - The Manufacturer
Aquatic Capital Management LLC Grows Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals (NasdaqGS:REGN) To Showcase Oncology And Respiratory Data At Major Conferences - simplywall.st
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’ - MSN
Regeneron Pharmaceuticals (REGN) Price Target Lowered by Guggenh - GuruFocus
Regeneron ordered to face lawsuit alleging Medicare fraud over Eylea - Seeking Alpha
Thyroid Eye Disease Pipeline 2025: MOA, ROA, and Clinical Trial - openPR.com
Regeneron to present new cancer treatment data at ASCO By Investing.com - Investing.com India
Regeneron to present new cancer treatment data at ASCO - Investing.com
Regeneron (REGN) to Unveil Key Oncology and Hematology Data at A - GuruFocus
Regeneron (REGN) to Showcase Dupixent Data at 2025 ATS Conferenc - GuruFocus
Regeneron (REGN) Faces Price Target Cut Amid Revenue Concerns | - GuruFocus
Regeneron (REGN) Faces Price Target Cut Amid Revenue Concerns | REGN Stock News - GuruFocus
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination - The Manila Times
Regeneron Pharmaceuticals to Present New Oncology and Hematology Data at 2025 ASCO Annual Meeting - Nasdaq
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases - Stock Titan
PDT Partners LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron (REGN) Faces Price Target Cut Amid Eylea Challenges | - GuruFocus
California State Teachers Retirement System Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Public Employees Retirement Association of Colorado - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Beacon Pointe Advisors LLC - MarketBeat
Stifel Financial Corp Has $27.13 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
MML Investors Services LLC Purchases 2,218 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Jim Cramer Listed 20 Best Performing Stocks of the Last 20 Years - Insider Monkey
Cantor Fitzgerald maintains Regeneron stock with $695 target By Investing.com - Investing.com South Africa
Robert W. Baird Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Another Regeneron CRL Prompts Regulatory Operations Questions - insights.citeline.com
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Regeneron Shares Are Up Today: What's Going On? - Benzinga
Guggenheim Cuts Regeneron Pharmaceuticals' Price Target to $810 From $940 - marketscreener.com
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
0.41%
大文字化:
|
ボリューム (24 時間):